Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Fai... ( Quark to initiate Phase 1 trial of AK...)

HOME >> MEDICINE >> TECHNOLOGY

Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)

Date:8/19/2007

Quark to initiate Phase 1 trial of AKIi-5 as the first human clinical study

involving the systemic delivery of siRNA

FREMONT, Calif., Aug. 2 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today the presentation of positive results from preclinical efficacy studies for its proprietary systemically-administered, siRNA compound, AKIi-5, in acute renal failure (ARF).

In the study, rats treated with a single bolus injection of rat AKIi-5, Quark's proprietary siRNA compound targeting the p53 gene, were significantly protected from ischemia/reperfusion-induced acute kidney injury. The compound was most efficacious when administered within a well-determined time window of 2-4 hours post injury. The study also proved that AKIi-5 has a favorable drug disposition (PK) profile, with short local exposure predominantly to the kidney-exhibiting rapid clearance of the drug post-administration. Quark's preclinical studies to date also indicate that AKIi-5 has a favorable safety profile, with a therapeutic index (toxic dose/effective dose) in rats greater than 250.

Elena Feinstein, M.D., Ph.D., the Company's Chief Scientific Officer, presented the results of the preclinical efficacy studies in a poster session at the Beyond Genome 2007 conference in San Francisco, CA. Quark's poster presentation was based on unpublished data. The studies were performed in collaboration with Bruce A. Molitoris, M.D., Director of the Division of Nephrology and Professor of Medicine at Indiana University School of Medicine, and lead academic investigator in the Quark program.

Daniel Zurr, CEO of Quark, commented, "Our pharmacokinetic, distribution, and toxicity studies indicate that siRNA-mediated, temporary inhibition of p53 by our systemically administered drug, AKIi-5, is a safe and efficient way to treat and prevent acute
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
2. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
3. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data on Molecular Imaging Pharmaceutical for Prostate Cancer
4. Molecular Insight Pharmaceuticals, Inc. Presents Preclinical Data at Society Of Nuclear Medicine 2007 Annual Meeting
5. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop

Post Your Comments:

(Date:5/23/2013)... May 23, 2013 Nephros, Inc. (OTC Bulletin ... device company that develops and sells high performance liquid ... rights offering. In addition, the concurrent temporary reduction in ... on May 17, 2013. Nephros estimates that ... the rights offering. A portion of the proceeds will ...

(Date:5/23/2013)... -- A recently published clinical study conducted at TOPS Comprehensive ... demonstrates that 3D mammography (breast tomosynthesis) significantly reduces unnecessary ... The study, "Implementation of Breast Tomosynthesis in a Routine ... Stephen L. Rose , MD, and published ... of Roentgenology (AJR). The AJR is the scientific ...

(Date:5/23/2013)... , May 23, 2013 More than half ... not benefit from chemotherapy and still have excellent outcomes. ... of one of the largest sources of online consumer ... and interactive Facebook page provide recently diagnosed women with ... safely avoid chemotherapy. "We anticipate these innovative ...

Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2 Nephros Announces Completion of Rights Offering 3 Nephros Announces Completion of Rights Offering 4 First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 2 First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams 3 Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 2 Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions 3

[0] Nephros Announces Completion of Rights Offering [0] First Large-Scale U.S. Study Validates the Benefits of 3D Mammography (Breast Tomosynthesis) Exams [0] Agendia Launches Social Media Campaigns to Help Breast Cancer Patients with Chemotherapy Decisions

... Mass. , May 5 LightLab Imaging, ... Optical Coherence Tomography (OCT) technology for vascular and other ... and Drug Administration (FDA) for the C7-XR Imaging System ... LightLab,s latest generation Frequency Domain OCT (FD-OCT™) technology, are ...

... May 5 Zimmer Holdings, Inc. (NYSE: ZMH ; SIX: ZMH) ... Care Conference in New York, New York , on May 11, 2010 , ... , , A live ... . The webcast will be archived for replay following the conference. , ...

Cached Medicine Technology:LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States 2 LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States 3 LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States 4 Zimmer Holdings to Present at Bank of America Merrill Lynch 2010 Health Care Conference 2

LightLab Imaging Announces FDA Clearance of C7-XR(TM) Coronary OCT Products in the United States Zimmer Holdings to Present at Bank of America Merrill Lynch 2010 Health Care Conference

(Date:5/25/2013)... York (PRWEB) May 25, 2013 ... litigation underway in U.S. District Court, Western District of ... According to a Case Management Order issued on ... the filing of contested motions in the Actos bladder ... motions. (In re: Actos Product Liability Litigation, MDL No. ...

(Date:5/25/2013)... May 25, 2013 Studies from Johns ... are carrying excessive weight and their inability to get ... simply losing weight can naturally relieve many symptoms. ... improvement in sleep quality was significantly associated with overall ... study dated November 6th, 2012, researchers monitored ...

(Date:5/25/2013)... (PRWEB) May 25, 2013 The ... ranging from irritable bowel syndrome (IBS) to bloating, ... among the most long-lasting, embarrassing, frustrating and difficult ... foods for digestive health have provided a ... are many factors contributing to digestive health issues, ...

(Date:5/25/2013)... (PRWEB) May 25, 2013 Dr. Farooq ... surgery clinic in Dubai, has announced his practice’s adoption ... is the only FDA-cleared femtosecond laser proven with more ... safety and precision of LASIK. , “We are happy ... Advanced Femtosecond Laser at our Dubai LASIK practice,” Ashraf ...

(Date:5/25/2013)... Prairie Living at Chautauqua , ... American Red Cross Blood Drive from 1:30 to 5:30 ... is located at 955 Villa Ct. in Carbondale, Illinois, ... Medicaid, who need some help to maintain their independence.. ... Andrea Arview Frey, Director of Marketing for Prairie Living. ...

Breaking Medicine News(10 mins):Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 2 Health News:Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation 3 Health News:hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep 2 Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2 Health News:Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method 2 Health News:Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive 2

[0] Actos Lawsuit News: Bernstein Liebhard LLP Notes New Case Management Order in Federal Actos Bladder Cancer Litigation [0] hCGTreatments / Diet Doc hCG Diets & Weight Loss Plans Offers Newly Improved hCG Diet Plans Capable of Delivering Better Sleep [0] Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org [0] Atlanta Vision Clinic Acquires the Latest in Blade-Free Lasik Technology Bringing Dubai Patients the Intralase Method [0] Carbondale Affordable Assisted Living Community to Host Red Cross Blood Drive

... New York Health AdvisoryNEW YORK, Feb. 12 Asthma ... in New York City, according to the United States ... suggests that there are many causes for asthma attacks, ... system changes that result from the presence, or lack ...

... Non-attorney Representation Services , ... Belleville, Ill. (PRWEB) February ... can increase their changes of getting awarded when they hire representation, ... the Social Security Disability Insurance (SSDI) process each year. ...

... doctors, nurses, and other medical personnel wear scrubs in the ... and ties to work. What we wear, as we ... comfortable, all the while maintaining our professionalism. With all ... someone go about making an important decision such as which ...

... has been enormous public controversy over the piece published ... stimulus bill. Betsy McCaughey, Ph.D. states:1) While ... Coordinator of Health Information Technology was created by former ... for doctors and hospitals that voluntarily adopted electronic medical ...

... RUTHERFORD, N.J., Feb. 11 Cambrex Corporation (NYSE: CBM ... period ended December 31, 2008., , ... quarter 2007 and full year sales decreased 3.7% excluding the impact ... for the quarter and year, respectively. , ...

... and MTA: CTIC) announced today that the Borsa Italiana, ... Company,s common stock on the MTA stock,market in Milan, ... on February 10th. As a result of the ... additionally been halted on the NASDAQ Stock Market,pursuant to ...

Home Care Tips for Reducing the Risk of Childhood Hospitalizations Due to Asthma Social Security Disability Applicants Increase Chances for Benefits with Representation So Many Nursing Scrubs, So Many Decisions: blue sky scrubs Offers Tips on How to Find That Perfect Set of Medical Scrubs Betsy McCaughey Responds to Poorly Informed Critics Cambrex Reports Fourth Quarter and Full Year 2008 Results Cell Therapeutics Updates Shareholders on Trading

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

Medicine Products:

Pb, Urine Parvovirus B19 Antibody, IgM Parvovirus B19 Antibodies, IgG & IgM Partial Thromboplastin Time with Reflex to PTT 1:1 Mix